[144] ABEONA THERAPEUTICS INC. SEC Filing

Rhea-AI Filing Summary

A Form 144 notice shows a proposed sale of 9,366 shares of common stock of Abeona Therapeutics, Inc. (ticker ABEO) by Brendan O'Malley. The shares are listed with an aggregate market value of $50,516.00 and the filer lists Nasdaq as the exchange. The filing states the shares were acquired as Restricted Stock Units on 09/29/2025 and payment is shown as cash. The table of recent sales also records a sale by Brendan O'Malley of 9,366 shares on 09/22/2025 for gross proceeds of $50,515.00. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.

Positive

• Compliance disclosure provided: The filer submitted a Rule 144 notice specifying quantity, acquisition type, and asserted no undisclosed material information
• Transaction transparency: The filing lists broker (Stifel Nicolaus) and exchange (Nasdaq), aiding market transparency

Negative

• Insider selling: An insider (Brendan O'Malley) is selling 9,366 shares, which may be interpreted by some market participants as dilution of insider ownership
• Limited context: The filing does not disclose any trading plan or reasons for the sale, which leaves rationale unclear

Insights

Securities Analyst

TL;DR: Insider Brendan O'Malley filed to sell 9,366 ABEO shares acquired as RSUs, a routine Rule 144 notification with limited market impact.

This Form 144 documents a proposed sale pursuant to Rule 144: 9,366 common shares with an aggregate market value of $50,516 and Nasdaq noted as the exchange. The shares are recorded as acquired via Restricted Stock Units on 09/29/2025 and paid in cash. The filing also lists a prior sale of identical share quantity on 09/22/2025 for $50,515. The filing contains the standard attestation regarding absence of undisclosed material information. There are no financial results, forward guidance, or corporate actions disclosed that alter the issuer's valuation in this notice.

Corporate Governance Expert

TL;DR: This is a procedural insider sale filing; it notifies the market but does not by itself indicate company-level changes.

The Form 144 provides required disclosure for an insider sale under Rule 144. It specifies acquisition source as Restricted Stock Units and confirms the seller's representation about material information. The form does not include details on any trading plan, lock-up waivers, or related-party transactions beyond the seller identity. As a governance disclosure, it meets notice requirements but contains no additional corporate governance events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	9366	50516.00	51156736	09/29/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/29/2025	Restricted Stock Units	Issuer			18188	09/29/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brendan O'Malley 6555 Carnegie Ave Fl 4 Cleveland OH 44103	Common Stock	09/22/2025	9366	50515.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 filed for ABEO disclose?

The Form 144 discloses a proposed sale of 9,366 Abeona Therapeutics common shares by Brendan O'Malley, with aggregate market value $50,516.00, to be sold on Nasdaq.

When and how were the shares being sold acquired?

The shares were acquired as Restricted Stock Units on 09/29/2025 and the filing shows payment as cash.

Did the filing report any prior sales by the same person?

Yes. The filing lists a sale by Brendan O'Malley of 9,366 shares on 09/22/2025 for gross proceeds of $50,515.00.

Which broker and exchange are named in the filing?

The broker is listed as Stifel Nicolaus & Company Inc and the exchange is Nasdaq.

Does the filing indicate undisclosed material information?

The seller signs a representation stating they do not know any material adverse information about the issuer that has not been publicly disclosed.